Some early experimental studies demonstrated elevated expression of ACE2, the SARS-CoV-2 receptor, following the use of RAASi, raising concerns regarding the safety of these agents that currently form the backbone for the treatment of hypertension and HF in the COVID-19 era [18,20]. The gene discussed is ACE2; the disease is hypertensive disorder.